Price Target Changed Today

 StocksRunner
 
  StocksRunner
 
Follow  Message
 
 
 
Find out what happening right now and get all the pieces of the puzzle on important data activity before the major news sources break the story and see what are the trends
 

•  08 Jan 2026
 

$AA JPMorgan reset expectations for Alcoa after a strong rally, lowering its price target to about $44 while shares trade near $61. With aluminum pricing showing signs of leveling out and RSI above 70, analysts are signaling valuation risk despite the broader uptrend, reminding traders that commodity momentum can cool fast.

$ACN Accenture continues to benefit from AI-driven optimism as UBS raised its price target to $320 while reiterating a Buy. Trading around $282 and holding an uptrend above key moving averages, the story is clear: enterprise demand for AI and data services remains resilient, reinforcing Accenture’s competitive edge.

$AMGN Amgen crossed above its average analyst target, trading near $330 versus a target around $329. While the trend remains positive, this milestone often marks a pause point, shifting investor focus toward pipeline execution and long-term earnings growth rather than further multiple expansion.

$BIRK Birkenstock pushed higher even as Bernstein cut its price target to $55 from $63. With shares near $44 and still in an uptrend, the market is balancing strong brand demand against potential fiscal 2026 headwinds, suggesting optimism remains but expectations are becoming more measured.

$BK Bank of New York Mellon gained credibility after Truist upgraded the stock to Buy. Trading near $120, the move highlights confidence in credit quality, fee-based revenue stability, and balance sheet strength, traits investors continue to favor in financials during uncertain macro conditions.

$BMY Bristol-Myers Squibb received an upgrade from UBS to Buy with a $62 target. Shares around $56 remain in an uptrend, reflecting renewed confidence in cash flow durability and pipeline visibility after a period of skepticism in large-cap pharma.

$COP ConocoPhillips saw its price target trimmed to $98 from $116, yet the stock trades close to that level near $99. The uptrend remains intact, suggesting analysts are normalizing expectations rather than calling for fundamental weakness in energy demand.

$CRDO Credo Technology faced a target cut to $200 from $240 while maintaining a Buy rating. With shares around $142 and a downtrend in place, the adjustment reflects near-term valuation pressure even as long-term AI infrastructure demand keeps the strategic thesis alive.

$CVX Chevron’s price target was trimmed but shares near $159 continue to move sideways above key averages. Analysts appear cautious on upside as commodity assumptions soften, while investors still value Chevron’s scale, dividends, and balance sheet strength.

$GLUE Monte Rosa Therapeutics moved above its average analyst target, trading in the mid-$20s. This breakout signals growing confidence in the clinical pipeline, though elevated RSI suggests expectations are rising quickly and future catalysts will matter more.

$KMI Kinder Morgan experienced a modest target trim while maintaining a Hold rating. Trading near $27 in an uptrend, the stock reflects steady infrastructure cash flows, with limited upside but defensive appeal in volatile markets.

$MLTX MoonLake Immunotherapeutics benefited from a higher price target, with shares around $14 after a sharp move. The strong trend suggests early-stage re-rating momentum as investors reassess the potential of its immunology pipeline.

$NUVB Nuvation Bio entered coverage with a Neutral rating and a target implying over 25% upside. Trading near $8.45 and holding an uptrend, the stock reflects cautious optimism balanced against development and execution risk.

$REGN Regeneron crossed above its average analyst target, trading just over $800. While the uptrend remains strong, this level often shifts the narrative toward sustained earnings delivery and pipeline depth rather than valuation expansion.

$RKT Rocket Companies edged above its average target near $21. With RSI elevated and an uptrend intact, optimism is tied to mortgage market stabilization, though sensitivity to rates remains a key variable.

$RVMD Revolution Medicines surged well above its average target, trading over $107. The powerful uptrend and high RSI highlight aggressive confidence in its oncology pipeline, but also increased sensitivity to upcoming clinical updates.

$SEI Solaris Energy Infrastructure received a higher price target while shares trade near $50. The sideways trend suggests consolidation after a strong run, as investors digest growth prospects tied to energy infrastructure demand.

$SIMO Silicon Motion crossed above its average analyst target before pulling back sharply to around $111. Despite the broader uptrend, the move illustrates how semiconductor names can overshoot analyst models quickly, forcing reassessment of valuation versus cycle risk.

View All Headlines